VA-HILTON-WORLDWIDE
Hilton Worldwide today announced the signing of a management agreement with Tokyo Humania Enterprise Inc. to re-brand Hotel Nikko Tokyo and manage the hotel as Hilton Tokyo Odaiba. On October 1, 2015, the property will be converted and unveiled as a new Hilton hotel, joining Hilton Worldwide’s existing portfolio of 11 operating and pipeline hotels in Japan and expanding the global hospitality brand’s footprint in the country.
Rob Palleschi, global head, full service brands, Hilton Worldwide, said, “Japan has always been a key market for us and we are delighted to add Hilton Tokyo Odaiba to our portfolio which now spans across key destinations such as Tokyo, Osaka, Nagoya, Okinawa and Fukuoka. Hilton is one of the most recognized brands in Japan and we look forward to providing both Japanese and international guests with the perfect stage to form memorable travel experiences with this new addition.”
“This signing underscores both the Hilton brand’s strength in Japan as well as our management capability, borne out of having operated here for more than 50 years, to drive exceptional experiences for both guests and owners,” said Andrew Clough, senior vice president of development, Middle East & Asia Pacific, Hilton Worldwide. “We look forward to partnering with Tokyo Humania Enterprise Inc. to launch Hilton Tokyo Odaiba as a strong addition to our portfolio. As we look ahead, it is important to add that we are thrilled at being able to play a part in supporting Japan’s efforts to deliver a showcase for the Tokyo 2020 Olympic & Paralympic games.”
A great base for leisure and business travelers, Hilton Tokyo Odaiba is strategically located in the waterfront area of Odaiba. Its immediate vicinity is a popular entertainment and shopping area featuring shopping malls, amusement park, bay cruise and parks with scenic views of the Tokyo Bay area. Hilton Tokyo Odaiba is well served by major roadways and train lines. It enjoys excellent accessibility to key business and commercial districts including Shinagawa and Ginza, and is approximately 8.5 kilometers away from the Marunouchi business district and 16 kilometers away from Tokyo International Airport (Haneda).
“Today’s announcement combines the expertise of a truly global, award-winning hospitality company with strong local market expertise. Given Hilton Worldwide’s extensive knowledge and 95 years of experience in operating world class hotels and resorts globally, with more than 50 years of experience in Japan, we are confident that Hilton Tokyo Odaiba will be another flagship hotel for Hilton Worldwide in Japan,” said Tatsuaki Makino, Representative Director, Tokyo Humania Enterprise Inc.
The 15-story Hilton Tokyo Odaiba will offer 453 guest rooms and suites, each with a private balcony that offers beautiful panoramic views of Tokyo Bay and the famous Rainbow Bridge. The hotel offers 10 food & beverage outlets including an all-day dining restaurant, a bar and eight specialty restaurants. Hilton Tokyo Odaiba has meetings and events facilities including a ballroom spanning 1,200 square meters, a business center as well as two wedding chapels. The hotel also features a fitness club, a spa and an indoor pool.
Hilton Tokyo Odaiba will become Hilton Worldwide’s sixth property in the Kanto area when it opens in October 2015, joining Conrad Tokyo, Hilton Tokyo, Hilton Odawara Resort & Spa, Hilton Tokyo Bay and Hilton Tokyo Narita Airport.
Read more about recent and upcoming Hilton Hotels & Resorts openings at http://news.hilton.com/openings . To view an interactive map featuring the Hilton Hotels & Resorts development pipeline visit http://news.hilton.com/map .
About Hilton Hotels & Resorts
Founded in 1919 as the flagship brand of Hilton Worldwide, Hilton Hotels & Resorts continues to build upon its legacy of innovation by developing products and services to meet the needs of savvy global travelers at more than 550 hotels across six continents. Hilton is the stylish, forward-thinking global leader in hospitality with Team Members shaping experiences in which every guest feels cared for, valued and respected. Access the latest news at news.hilton.com and begin your journey at www.hilton.com or www.hilton.com/offers for the latest hotel specials. Hilton Hotels & Resorts is one of Hilton Worldwide’s 12 brands.
About Hilton Worldwide
Hilton Worldwide (NYSE: HLT) is a leading global hospitality company, spanning the lodging sector from luxury and full-service hotels and resorts to extended-stay suites and focused-service hotels. For 95 years, Hilton Worldwide has been dedicated to continuing its tradition of providing exceptional guest experiences. The company's portfolio of twelve world-class global brands is comprised of more than 4,300 managed, franchised, owned and leased hotels and timeshare properties, with more than 715,000 rooms in 94 countries and territories, including Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages an award-winning customer loyalty program, Hilton HHonors®. Visit news.hiltonworldwide.com for more information and connect with Hilton Worldwide at www.facebook.com/hiltonworldwide , www.twitter.com/hiltonworldwide , www.youtube.com/hiltonworldwide , www.flickr.com/hiltonworldwide , and www.linkedin.com/company/hilton-worldwide .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150320005087/en/
Contact:
Audrey Wong
Hilton Worldwide – Asia Pacific
+65 6833 9763
audrey.wong@hilton.com
or
Jacqueline
Toppings
Hilton Worldwide
+ 1 703 883 5381
jacqueline.toppings@hilton.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum